Although further improvements on drug selection, delivery, and efficacy should be investigated, this work paves the way for developing a viable therapy for CMT patients affected by TyrRS mutations through regulating nuclear trafficking of the translation factor. The gene discussed is YARS1; the disease is Charcot-Marie-Tooth disease.